All Lung Cancer Studies

SCCA Clinical Studies: Lung Cancer

 

ABRAXANE® (Nab-Paclitaxel) for Advanced NSCLC (7755)
A Phase II Study of Weekly ABRAXANE® (Nab-Paclitaxel) for Patients with Advanced NSCLC with EGFR Mutations Following Front-Line Therapy with EGFR Tyrosine Kinase Inhibitors

Investigator: Christina Baik;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT01620190

SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy (8180)
Pulmonary Functional Imaging for Radiation Treatment Planning for Lung Cancer

Investigator: Jing Zeng;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT01982123

Proton Beam Radiation Therapy for Recurrent Thoracic Cancer (9148)
Definitive Re-Irradiation with Proton Beam Radiotherapy for Patients with Recurrent Thoracic Cancers

Investigator: Jing Zeng;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT02204761

MEDI4736 + Tremelimumab for Advanced Non-Small Cell Lung Cancer (20131955)
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736, in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer

Investigator: Sylvia Lee, MD;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT02000947

PF-06747775 for Advanced EGFRm Non-Small Cell Lung Cancer (20150645)
Phase 1/2 Open-Label Study of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) in Patients with Advanced Epidermal Growth Factor Receptor Mutant (DEL 19 OR L858R +/- T790M) Non-Small Cell Lung Cancer

Investigator: Renato Martins, MD, MPH;   Conditions: Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT02349633

Genetically Modified T Cells for Stage III-IV Lung Cancer or Mesothelioma (2727)
Phase I/II study in WT1-expressing non-small cell lung cancer and mesothelioma, comparing cellular adoptive immunotherapy with polyclonal autologous central memory to naïve CD8+ T cells that have been transduced to express a WT1-specific T cell receptor

Investigator: Sylvia Lee, MD;   Conditions: Lung Cancer, Mesothelioma;    Status: Recruiting;   Study ID: NCT02408016

Oral Ceritinib for ALK-positive Non-Small Cell Lung Cancer (NSCLC) Metastatic to Brain and/or Leptomeninges (20150427)
A Phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-positive non-small cell lung cancer (NSCLC) metastatic to the brain and/or to leptomeninges

Investigator: Christina S. Baik, MD, MPH;   Conditions: Non-Small Cell Lung Cancer (NSCLC);    Status: Recruiting;   Study ID: NCT02336451

ID-LV305 for Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Investigator: Seth M. Pollack, MD;   Conditions: Breast Cancer, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer, Sarcoma;    Status: Closed;   Study ID: NCT02122861

MGCD265 for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (20151071)
Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Investigator: Keith Eaton, MD, PhD;   Conditions: Lung Cancer; Non-Small-Cell (NSCLC);    Status: Recruiting;   Study ID: NCT02544633

Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed for Non-Small Cell Lung Cancer
A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer

Investigator: Rafael Santana-Davila;   Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT02657434

Rovalpituzumab Tesirine (SC16LD6.5) for Small Cell Lung Cancer Third-line and Later Treatment
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)

Investigator: Rafael Santana-Davila;   Conditions: Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT02674568

MPDL3280A for Metastatic Non-Small Cell Lung Cancer (9490)
A Pilot Study of MPDL3280A (PD-L1 Antibody Therapy and Hypofractionated Image-guided Radiotherapy (HIGRT) in Patients with Metastatic Non-Small Cell Lung Cancer (UMCC 2015.005)

Investigator: Ramesh Rengan, MD;   Conditions: Lung Cancer; Non-Small Cell Lung Cancer (NSCLC);    Status: Recruiting;   Study ID: NCT02463994

Photon Therapy Vs. Proton Therapy for Non-small Cell Lung Cancer (RTOG 1308)
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC

Investigator: Ramesh Rengan, MD;   Conditions: Non-small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01993810

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Investigator: Renato G. Martins, MD;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT02194738

Erlotinib Hydrochloride for Stage IB-IIIA NSCLC That Has Been Completely Removed by Surgery (Alliance A081105l)
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Investigator: Rafael Santana-Davila, MD ;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT02193282

Crizotinib for Stage IB-IIIA NSCLC w/ALK Fusion Mutations--Post Surgery (ECOG-ACRIN E4512)
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Investigator: Rafael Santana-Davila, MD ;   Conditions: Non-small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT02201992

Biomarker-Targeted Second-Line Therapy for Recurrent Stage IIIB-IV Squamous Cell Lung Cancer (SWOG 1400)
S1400 Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Investigator: Christina S. Baik, MD;   Conditions: Non-small Cell Lung Cance;    Status: Recruiting;   Study ID: NCT02154490

MGCD516 for Advanced Solid Tumor Malignancies (20150094)
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

Investigator: Keith Eaton, MD, PhD;   Conditions: Solid Tumors;    Status: Recruiting;   Study ID: NCT02219711

FLARE RT for Stage IIB-IIIB Non-small Cell Lung Cancer
Personalized Radiation Therapy Through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT)

Investigator: Jing Zeng, MD;   Conditions: Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT02773238